Sandoz Fights FDA Exclusivity For Sanofi Blockbuster
Novartis unit Sandoz has accused the U.S. Food and Drug Administration of improperly giving exclusivity to a Sanofi multiple sclerosis drug even though its active ingredient was present in an earlier...To view the full article, register now.
Already a subscriber? Click here to view full article